biolog
tissu
among
mani
clinic
option
avail
orthoped
surgeon
million
annual
implant
human
allograft
alon
biolog
tissu
may
consid
structur
exampl
tendon
cortic
bone
strut
nonstructur
ground
deminer
bone
matric
dbm
amniot
membran
intend
use
may
mimic
origin
anatom
function
use
patellar
ligament
anterior
cruciat
ligament
acl
reconstruct
cortic
bone
segment
repair
longbon
fractur
circumst
use
may
differ
origin
anatomi
use
dermal
layer
rotat
cuff
repair
ground
amniot
membran
combin
deminer
cortic
bone
spine
fusion
procedur
chapter
focus
intent
scienc
variou
mean
process
human
allograft
tissu
ensur
safeti
clinic
use
although
xenograft
deriv
nonhuman
sourc
found
clinic
use
varieti
surgic
disciplin
includ
use
porcin
heart
valv
heart
valv
replac
surgeri
ground
bovin
bone
dental
procedur
use
orthoped
surgeri
met
limit
use
success
particular
porcinederiv
small
intestin
submucosa
perform
well
tissu
augment
materi
bovin
tendon
commonli
use
thu
xenograft
discuss
chapter
although
autograft
taken
directli
patient
wide
use
procedur
acl
reconstruct
spinal
implant
iliac
crest
segment
graft
subject
signific
process
clean
shape
sutur
attach
intrasurgeri
transplant
therefor
also
cover
chapter
autograft
materi
use
autolog
cartilag
implant
bloodderiv
prepar
plateletrich
plasma
describ
elsewher
book
use
orthoped
surgeon
allograft
commonli
process
physic
chemic
biochem
mean
process
step
typic
perform
accomplish
one
object
reduc
risk
diseas
transmiss
eg
variou
disinfect
steril
step
reduc
immunogen
respons
eg
decellular
reduc
barrier
optim
physiolog
activ
eg
deminer
cortic
bone
enhanc
bioavail
growth
factor
physic
convert
graft
usabl
form
eg
shape
bone
graft
placement
intervertebr
bodi
spacer
combin
graft
synthet
enhanc
eas
use
eg
combin
ground
deminer
bone
carrier
produc
puttylik
materi
preserv
tissu
increas
shelf
life
simplifi
storag
eg
lyophil
ground
bone
enabl
retent
ambient
temperatur
focu
human
allograft
brief
histor
regulatori
perspect
provid
background
follow
section
reduct
diseas
transmiss
enhanc
fusion
potenti
bone
void
filler
lower
immunogen
respons
decellular
preserv
method
futur
direct
human
allograft
use
orthoped
surgeri
mani
decad
centuri
william
macewen
describ
success
use
allogen
cortic
bone
fragment
graft
replac
miss
humer
midshaft
year
ago
fred
albe
publish
long
list
surgic
use
bone
allograft
includ
applic
state
abl
past
year
avoid
entir
use
metal
intern
bone
fixat
purpos
made
possibl
larg
util
best
well
known
mechan
devic
hitherto
rare
use
surgeri
bone
inlay
wedg
dowel
tongu
groov
joint
mortis
dovetail
joint
centuri
bone
graft
continu
use
tendon
allograft
start
gain
widespread
accept
midto
centuri
bone
bank
allograft
hospitalbas
tissu
deriv
deceas
amput
patient
tissu
often
underw
minim
chemic
process
antibiot
disinfect
soak
addit
physic
alter
tissu
typic
perform
surgic
team
time
implant
includ
bone
shape
grind
tendon
trim
sutur
answer
need
better
defin
method
ensur
graft
safeti
consist
well
appropri
respect
tissu
donor
famili
formal
system
began
establish
navi
tissu
bank
bethesda
md
tissu
bank
standard
regul
latter
half
centuri
methodolog
practic
develop
navi
tissu
bank
increasingli
adopt
organ
american
associ
tissu
bank
aatb
form
issu
first
set
tissueprocess
standard
establish
guidelin
accept
time
death
recoveri
storag
condit
tissu
microbi
test
requir
definit
deminer
freezedri
forth
certif
program
also
establish
assur
surgic
commun
qualifi
tissu
bank
met
aatb
standard
similarli
around
turn
centuri
us
food
drug
administr
fda
develop
classif
human
cell
tissu
product
hctp
separ
regulatori
classif
human
tissu
transplant
fell
classif
appli
human
tissu
transplant
differ
medic
devic
classif
qualifi
hctp
tissu
need
meet
standard
exceed
minim
manipul
origin
relev
characterist
alter
also
homolog
use
mean
tissu
use
clinic
similar
manner
intend
bodi
origin
clear
exampl
tissu
meet
requir
would
hamstr
tendon
recov
intact
disinfect
steril
use
tendon
replac
convers
although
bone
void
filler
putti
contain
dbm
would
consid
homolog
use
may
consid
minim
manipul
addit
synthet
carrier
thu
classifi
medic
devic
requir
fda
clearanc
distribut
exampl
disinfect
freezedri
cortic
bone
segment
use
intervertebr
bodi
spacer
consid
minim
manipul
intend
homolog
use
processor
continu
becom
innov
use
treatment
human
tissu
definit
undoubtedli
test
clarifi
ad
regulatori
safeguard
especi
respect
risk
diseas
transmiss
fda
issu
interim
rule
requir
certain
infecti
diseas
test
donor
screen
recordkeep
facil
help
prevent
transmiss
aid
hepat
human
tissu
use
transplant
gener
method
reduc
risk
diseas
transmiss
antibiot
soak
peroxid
disinfect
steril
use
radiat
method
consid
minim
manipul
regulatori
front
fda
establish
conjunct
tissu
bank
input
standard
good
tissu
practic
creat
unifi
registr
list
system
establish
manufactur
hctp
establish
donor
elig
current
good
tissu
practic
procedur
prevent
introduct
transmiss
spread
communic
diseas
summari
us
system
aatb
standard
fda
regul
inspect
provid
mani
safeguard
provis
effect
transplant
allograft
tissu
human
tissu
carri
inher
yet
minim
risk
diseas
transmiss
made
essenti
neglig
advanc
clean
process
methodolog
survey
aatb
estim
overal
allograftassoci
infect
rate
import
note
survey
preced
widespread
implement
advanc
method
aim
reduc
risk
diseas
transmiss
includ
fdamand
sensit
nucleic
acid
test
nat
certain
virus
well
routin
termin
steril
although
welldocu
case
diseas
transmiss
occur
modern
tissu
bank
practic
process
success
diminish
incid
last
decad
case
begin
four
organ
allograft
tissu
distribut
hivinfect
donor
favor
screen
histori
neg
serolog
test
four
organ
recipi
three
recipi
receiv
fresh
frozen
bone
tissu
test
posit
hiv
investig
suspect
transmiss
occur
seroneg
donor
recent
becom
infect
window
period
yet
develop
antibodi
detect
test
use
time
anoth
case
surfac
recipi
receiv
organ
tissu
donor
infect
hepat
c
viru
hcv
consequ
develop
hcv
infect
earlier
hiv
transmiss
case
donor
seroneg
hcv
nat
perform
subsequ
nat
store
serum
donor
detect
viru
highlight
import
use
sensit
test
releas
donor
tissu
nat
hiv
hcv
requir
fda
ad
requir
aatb
also
report
case
transmiss
tuberculosi
variou
clostridium
speci
group
streptococci
rabi
overal
rel
risk
diseas
transmiss
small
consid
million
allograft
transplant
howev
possibl
transmiss
make
avoid
control
reduct
microbi
viral
bioburden
integr
tissueprocess
practic
allograft
tissu
provid
reduc
risk
diseas
transmiss
three
primari
mean
minim
occurr
process
donor
tissu
unaccept
bioburden
control
environ
tissuehandl
practic
avoid
contamin
reduc
remain
bioburden
disinfect
steril
techniqu
first
categori
occurr
recov
process
tissu
contamin
minim
stringent
bioburden
test
includ
anaerob
aerob
cultur
test
bacteria
fungi
well
serolog
test
nat
detect
specif
virus
specif
test
requir
fda
also
meet
aatb
standard
note
proper
infecti
diseas
test
must
valid
use
specif
cadaver
specimen
detail
donorscreen
process
also
critic
minim
bioburden
medic
record
social
histori
travel
tattoo
highrisk
sexual
behavior
illicit
drug
use
incarcer
well
physic
examin
help
assess
donor
elig
second
categori
bioburden
load
control
use
asept
handl
techniqu
recoveri
process
prevent
contamin
tissu
pathogen
howev
import
note
use
asept
condit
prevent
addit
contamin
reduc
elimin
exist
bioburden
third
riskreduct
categori
process
method
design
reduc
remain
bioburden
address
follow
section
bioburden
load
reduc
clean
disinfect
tissu
step
vari
tissu
type
may
includ
debrid
low
dose
preirradi
irradi
chemic
process
step
physic
method
lavag
pulsatil
fluid
flow
centrifug
fluid
bath
rotat
sonic
enzymat
digest
cellular
materi
penetr
agent
supercrit
co
combin
chemic
activ
milder
chemic
includ
alcohol
deterg
antibiot
aggress
chemic
naoh
aceton
peroxid
clean
process
remov
bone
marrow
element
lipid
lowmolecularweight
protein
thu
reduc
graft
immunogen
potenti
well
bacteri
viral
fungal
contamin
aggress
agent
may
commonli
use
disinfect
bone
hydrogen
peroxid
typic
use
soft
tissu
graft
least
one
process
includ
use
hydrogen
peroxid
tendon
correl
signific
increas
risk
revis
acl
repair
case
howev
contribut
hydrogen
peroxid
appar
graft
weaken
unclear
process
also
includ
pulsatil
fluid
flow
cellular
remnant
presum
associ
infecti
agent
may
also
remov
tissu
decellular
method
also
discuss
later
section
method
includ
use
chemic
nondenatur
anion
deterg
recombin
endonucleas
sodium
dodecyl
sulfat
sodium
hydroxid
sodium
peroxid
sodium
chlorid
antibiot
assur
tissu
steril
process
reduc
elimin
bioburden
tissu
typic
either
test
steril
subject
termin
steril
step
test
steril
usual
involv
sampl
portion
tissu
process
solut
accord
unit
state
pharmacopeia
steril
test
guidelin
packag
import
note
unit
state
pharmacopeia
label
necessarili
indic
tissu
product
steril
rather
sampl
product
batch
cultur
neg
thu
pass
test
steril
altern
test
steril
tissu
may
process
packag
subject
steril
placement
final
packag
thu
terminu
process
case
termin
steril
chosen
method
must
effect
penetr
packag
option
discuss
subsequ
section
term
measur
steril
absolut
assur
steril
probabilist
feasibl
measur
known
steril
assur
level
commonli
refer
sal
design
indic
degre
level
assur
steril
achiev
valid
steril
process
two
common
sal
allograft
product
label
sal
indic
chanc
singl
viabl
microb
present
tissu
wherea
sal
indic
greater
degre
steril
chanc
sal
requir
level
steril
center
diseas
control
prevent
medic
instrument
breach
skin
thu
often
refer
medic
devic
level
steril
level
steril
achiev
termin
steril
though
termin
steril
tissu
product
still
retain
sal
note
sal
measur
microbi
steril
unrel
virus
although
method
use
achiev
accept
sal
may
effect
lower
viral
risk
mention
previous
tissu
processor
use
strict
donorscreen
viral
test
method
prevent
viral
transmiss
furthermor
sever
process
method
demonstr
result
signific
viral
inactiv
exampl
lowdos
gamma
irradi
demonstr
inactiv
broad
spectrum
virus
includ
hiv
envelop
nonenvelop
dna
rna
virus
anoth
process
method
use
vacuum
oscil
pressur
combin
chemic
agent
inactiv
pathogen
use
termin
steril
process
abil
inactiv
wide
rang
viru
type
particularli
advantag
new
virus
eg
zika
sever
acut
respiratori
syndrom
forth
emerg
valid
blood
test
may
yet
exist
report
method
termin
steril
allograft
final
packag
includ
plasma
h
ethylen
oxid
eo
supercrit
co
electron
beam
irradi
gamma
irradi
benefit
risk
plasma
h
disadvantag
remov
osteoinduct
potenti
dbm
may
damag
soft
tissu
although
eo
commonli
use
steril
medic
instrument
report
caus
persist
synovi
effus
inflammatori
respons
eotreat
allograft
supercrit
co
electron
beam
irradi
report
capabl
safe
provid
termin
steril
without
significantli
damag
tissu
howev
process
rel
unproven
clinic
account
small
percentag
steril
tissu
frequent
use
method
termin
steril
gamma
irradi
gamma
irradi
common
steril
treatment
method
use
allograft
also
use
major
process
tendon
whether
termin
steril
intermedi
step
although
report
neg
outcom
gammairradi
allograft
tissu
studi
either
first
treat
harsh
chemic
pretreat
appli
irradi
higher
less
desir
temperatur
studi
demonstr
use
irradi
graft
neg
affect
clinic
efficaci
interpret
inconsist
result
import
note
four
key
variabl
allow
reader
accur
evalu
method
use
appli
gamma
irradi
potenti
impact
clinic
outcom
four
key
variabl
includ
target
dose
dose
rang
temperatur
irradi
tissu
treatment
irradi
target
dose
refer
intend
dose
deliv
tissu
although
tissu
actual
receiv
rang
dosag
due
natur
irradi
dose
rang
precis
descript
convey
minimum
maximum
amount
radiat
exposur
graft
receiv
narrow
dose
rang
indic
higher
degre
control
bone
allograft
irradi
approxim
kgi
mrad
shown
similar
clinic
result
nonirradi
bone
irradi
dosag
greater
may
neg
impact
biomechan
properti
although
clinic
signific
unclear
soft
tissu
allograft
report
perform
well
treat
kgi
mrad
irradi
allograft
low
temperatur
eg
dri
ice
also
shown
effect
mitig
potenti
damag
graft
minim
gener
free
radic
temperatur
irradi
provid
studi
may
indic
graft
irradi
ambient
temperatur
prone
damag
thu
temperatur
irradi
alway
taken
account
analyz
result
studi
studi
report
result
come
graft
irradi
ambient
temperatur
import
note
outcom
accur
appli
graft
care
irradi
ultralow
temperatur
support
review
case
acl
repair
tejwani
et
al
find
increas
risk
revis
surgeri
use
two
proprietari
process
use
lowdos
mrad
gamma
irradi
appli
low
temperatur
outcom
along
find
studi
support
clinic
efficaci
lowtemperatur
irradi
steril
tendon
summari
advanc
tissu
recoveri
process
method
includ
step
ensur
bioburden
prevent
control
reduct
howev
method
use
tissu
processor
vari
step
result
differ
among
avail
allograft
tissu
may
either
offer
asept
termin
steril
step
reach
sal
type
termin
steril
use
also
differ
impact
clinic
perform
allograft
tissu
lowdos
gamma
irradi
low
temperatur
still
common
method
welldocu
success
benchtop
studi
shown
encourag
earli
result
supercrit
co
electron
beam
irradi
enhanc
fusion
potenti
allograft
bone
void
filler
bone
allograft
long
use
provid
structur
support
fill
void
tradit
graft
process
previous
describ
reduc
risk
diseas
transmiss
also
meet
specif
surgic
dimension
need
cut
machin
grind
tradit
allograft
cortic
strut
ground
cortic
bone
cancel
cube
femor
head
shape
interbodi
spacer
play
continu
play
promin
role
orthoped
surgeri
addit
review
chapter
acceler
fusion
object
orthoped
surgeon
also
wide
array
advanc
option
facilit
new
bone
growth
breakthrough
field
came
discoveri
certain
extract
bone
element
could
promot
bone
growth
subsequ
marshal
urist
colleagu
isol
proteinac
factor
found
stimul
induc
new
bone
format
famili
osteoinduct
protein
name
bone
morphogen
protein
bmp
recogn
three
key
properti
requir
new
bone
format
growth
osteoconduct
scaffold
osteoinduct
signal
bmp
osteogen
cell
order
new
bone
must
scaffold
grow
refer
osteoconduct
matrix
cytokin
signal
requir
induc
precursor
cell
either
differenti
toward
osteoblast
lineag
cell
express
osteoblast
phenotyp
bone
format
factor
thu
consid
osteoinduct
final
new
bone
growth
requir
presenc
boneform
cell
osteoblast
precursor
produc
extracellular
miner
matrix
cellular
compon
refer
osteogen
differ
bonegraft
option
may
provid
one
two
three
properti
exampl
process
cancel
cube
still
consid
osteoconduct
scaffold
capabl
support
new
bone
growth
interact
host
bone
signal
despit
potenti
neither
signific
osteoinduct
capac
low
nativ
growth
factor
osteogen
potenti
devit
anoth
exampl
recombin
form
one
commerci
avail
specif
human
growth
factor
would
consid
osteoinduct
signal
would
requir
addit
presenc
osteogen
osteoconduct
compon
drive
bone
format
furthermor
autograft
bone
marrow
mixtur
deriv
patient
may
theoret
provid
three
compon
necessari
new
bone
format
quantiti
qualiti
graft
materi
may
depend
surgic
site
health
age
patient
altern
viabl
cellular
allograft
theoret
provid
three
compon
describ
follow
section
beyond
simpli
fill
bone
void
allograft
also
process
differ
manner
enhanc
fusion
potenti
preval
process
method
involv
take
advantag
pervas
nativ
bmp
found
cortic
bone
care
deminer
factor
becom
bioavail
result
dbm
typic
dilut
hydrochlor
acid
solut
use
dissolv
bone
miner
phase
apatit
calcium
phosphat
thu
expos
growth
factor
fact
process
mimic
natur
action
osteoclast
bone
remodel
creat
local
acid
environ
similarli
dissolv
miner
phase
releas
bmp
signal
cell
lay
new
bone
undertr
hypodeminer
would
result
osteoinduct
factor
still
trap
bone
matrix
unavail
rapid
signal
wherea
hyperdeminer
may
lead
factor
either
elut
matrix
deminer
overli
acidexpos
denatur
thu
yield
nonosteoinduct
materi
least
one
studi
demonstr
relationship
correl
residu
calcium
level
measur
deminer
new
bone
format
use
rodent
bone
growth
model
author
support
premis
overdeminer
underdeminer
lower
osteoinduct
potenti
dbm
indic
optim
rang
middl
thu
given
presenc
bioavail
growth
factor
within
human
boni
matrix
properli
deminer
dbm
consid
osteoinduct
osteoconduct
still
reli
patient
cell
osteogen
compon
improv
handl
mani
dbm
formul
also
use
carrier
glycerol
hyaluron
acid
starch
forth
extens
studi
impact
carrier
longterm
clinic
outcom
gener
lack
although
clinic
evid
support
glycerol
hyaluron
acid
dbm
carrier
recent
cellular
bone
allograft
emerg
new
option
graft
formul
provid
three
element
bone
format
osteoconduct
compon
bone
form
chip
fiber
particul
osteogen
compon
compris
cell
either
adher
bone
compon
ad
anoth
sourc
exampl
adiposederiv
cell
amniot
tissu
osteoinduct
compon
may
dbm
deriv
donor
may
reli
endogen
trophic
factor
inher
cellular
compon
current
cellular
bone
void
filler
approach
reli
inclus
mesenchym
stem
cell
assum
produc
factor
conduc
heal
process
differenti
osteoblast
lineag
initi
bone
format
impact
patient
local
environ
differenti
pathway
time
well
understood
question
becom
increasingli
complex
cell
compon
deriv
nonbon
sourc
placenta
adipos
tissu
altern
cellular
bone
void
filler
includ
live
cell
integr
donor
bone
thu
bone
cell
alreadi
commit
osteoblast
lineag
longer
term
control
clinic
data
would
benefici
help
support
provid
orthopedist
singl
graft
materi
three
compon
bone
format
allograft
gener
consid
nonimmunogen
either
due
natur
human
tissu
transplant
human
consequ
clean
process
remov
cellular
materi
bone
marrow
element
preserv
process
includ
freez
freezedri
howev
depend
tissu
type
intend
clinic
applic
unprocess
allograft
tissu
pose
issu
immunogen
need
minim
allograft
optim
biocompat
upon
implant
furthermor
differ
type
tissu
exhibit
vari
degre
immunogen
measur
antigen
skin
gener
immunogen
bone
tendon
tissu
exhibit
lower
immunogen
gener
resolv
typic
allograftclean
process
immunogen
tissu
may
need
altern
process
lower
antigen
one
method
treat
tissu
glutaraldehyd
aldehyd
fix
greatli
reduc
immunogen
crosslink
antigen
howev
glutaraldehyd
associ
allerg
reaction
may
contribut
extrem
high
acl
failur
rate
report
one
studi
anoth
method
frequent
appli
dermal
tissu
use
decellular
reduc
potenti
immunogen
intend
yield
biocompat
scaffold
favor
environ
host
recellular
remodel
although
sever
differ
decellular
method
use
common
goal
elimin
cellular
remnant
could
caus
immun
respons
preserv
tissu
architectur
maintain
mechan
properti
scaffold
dermal
tissu
decellular
scaffold
use
orthoped
procedur
superior
capsul
shoulder
reconstruct
achil
tendon
repair
other
note
previous
decellular
process
includ
chemic
mechan
extract
method
specif
decellular
techniqu
report
use
anion
agent
eg
sodium
dodecyl
sulfat
sodium
chlorid
alkali
compound
eg
sodium
hydroxid
oxid
agent
eg
hydrogen
peroxid
solubil
cellular
remnant
remov
howev
type
chemic
use
durat
decellular
process
affect
strength
graft
remov
collagen
glycosaminoglycan
addit
immunogen
compon
make
differ
among
decellular
process
worthi
consider
amount
cellular
remnant
remain
decellular
may
indic
use
residu
dna
content
lower
dna
content
would
theoret
indic
cleaner
matrix
favor
host
respons
residu
dna
content
graft
vari
wide
publish
report
includ
rang
less
greater
dnamg
dri
weight
acellular
dermal
matrix
adm
tissu
residu
dna
level
may
correl
host
respons
surpris
differ
adm
incorpor
differ
rate
specif
note
adm
lower
residu
dna
content
found
rapidli
integr
recellular
compar
anim
model
recellular
adm
implant
host
cell
may
begin
repopul
scaffold
initi
incorpor
graft
process
start
migrat
inflammatori
host
cell
follow
matrix
remodel
final
revascular
lead
recellular
although
exact
mechan
host
integr
fulli
understood
differ
incorpor
rate
like
begin
initi
process
initi
inflammatori
host
respons
mediat
macrophag
monocyt
must
achiev
care
balanc
wound
heal
tissu
destruct
macrophag
regul
express
cytokin
contribut
woundheal
process
control
fibroblast
activ
macrophag
phenotyp
associ
inflammatori
respons
wherea
macrophag
phenotyp
associ
tissu
repair
construct
tissu
remodel
agraw
et
al
investig
mechan
incorpor
examin
effect
macrophag
phenotyp
express
matrix
remodel
use
three
differ
human
adm
one
syntheticbovin
adm
adm
product
display
differ
pattern
time
macrophag
infiltr
lead
author
conclud
variabl
due
distinct
decellular
process
use
adm
product
capito
et
al
also
conclud
differ
decellular
process
may
account
vari
degre
cellular
vascular
ingrowth
shown
four
differ
materi
studi
discuss
chapter
decellular
benefici
reduc
immunogen
certain
tissu
type
differ
method
result
differ
rate
recellular
may
impact
incorpor
rate
ultim
tissu
remodel
unlik
organ
composit
tissu
allotranspl
typic
transplant
within
hour
donor
death
allograft
may
store
week
year
use
consequ
graft
must
process
way
maintain
safeti
clinic
efficaci
extend
period
time
addit
process
steril
method
describ
previous
anoth
factor
impact
use
clinic
effect
allograft
manner
preserv
store
handl
use
current
allograft
preserv
typic
includ
use
storag
media
cryopreserv
freezedri
store
graft
ambient
refriger
frozen
state
storag
temperatur
determin
requir
ship
onsit
storag
presurgeri
prepar
sever
main
consider
concern
preserv
storag
allograft
tissu
cell
viabil
applic
maintain
structur
integr
nativ
properti
bone
extracellular
matrix
conveni
storag
use
section
review
main
type
preserv
storag
well
advantag
disadvantag
arrang
storag
temperatur
follow
preserv
method
applic
method
also
summar
tabl
simplest
type
preserv
store
asept
recov
tissu
refriger
howev
simplic
preserv
beli
complex
logist
involv
use
socal
fresh
tissu
current
fresh
graft
limit
shelf
life
releas
expir
implant
commonli
use
fresh
tissu
orthoped
surgeri
osteochondr
allograft
use
cartilag
restor
knee
shoulder
talu
advantag
preserv
type
maintain
viabl
cell
case
osteochondr
graft
includ
viabl
chondrocyt
may
help
restor
recipi
articular
surfac
live
cell
immunoprivileg
requir
immunosuppress
make
graft
type
advantag
donor
cell
contribut
gener
collagen
extracellular
matrix
maintain
viabl
cell
tissu
processor
asept
recov
tissu
take
cultur
debrid
disinfect
size
treat
antibiot
tissu
processor
avoid
use
method
remov
cellular
materi
either
deliber
use
decellular
process
previous
discuss
incident
result
type
chemic
physic
clean
process
process
allograft
packag
store
quarantin
bacteri
fungal
viral
test
result
obtain
storag
time
critic
factor
graft
studi
shown
cell
viabil
decreas
time
storag
media
also
impact
cell
viabil
area
ongo
research
develop
graft
clear
distribut
current
graft
expir
time
gener
fewer
day
includ
quarantin
period
surgeri
reason
schedul
suitabl
match
found
short
window
avail
contribut
logist
complex
involv
use
fresh
allograft
despit
challeng
fresh
osteochondr
allograft
becom
popular
although
fresh
tissu
advantag
particular
circumst
current
time
constraint
make
use
challeng
surgeon
patient
hospit
tissu
processor
alik
unlik
fresh
refriger
tissu
frozen
allograft
may
store
year
implant
freez
without
use
special
cryopreserv
method
solut
caus
format
ice
crystal
within
cell
extracellular
matrix
result
lysi
therefor
type
preserv
use
allograft
mainten
viabil
object
structur
bone
allograft
tendon
acellular
dermi
frozen
graft
process
cryopreserv
process
gener
includ
pathogen
test
debrid
clean
disinfect
remov
remnant
cell
marrow
lipid
bioburden
frozen
store
tissu
contain
live
cell
exampl
cellular
bone
void
filler
osteochondr
graft
cryopreserv
solut
use
cryopreserv
extend
storag
time
tissu
requir
viabl
cell
avoid
logist
timesensit
issu
note
fresh
refriger
allograft
cryopreserv
method
includ
control
rate
freez
process
reduc
format
ice
crystal
remov
water
cell
replac
cryopreserv
common
cryopreserv
includ
glycerol
dimethyl
sulfoxid
tissu
process
treat
cryopreserv
slowli
cool
cryogen
temperatur
cryopreserv
allograft
either
store
ultralowtemperatur
freezer
use
liquid
nitrogen
maintain
temperatur
transit
phase
ice
amorph
glass
prevent
reform
ice
crystal
maintain
state
tissu
sever
year
preserv
method
allow
longer
storag
time
allograft
requir
viabl
cell
cellular
bone
void
filler
osteochondr
graft
avoid
complex
time
logist
seen
fresh
allograft
howev
tissu
must
remain
frozen
use
therefor
requir
special
ship
condit
well
onsit
storag
valid
freezer
monitor
temperatur
frozen
tissu
may
also
requir
lengthi
thaw
time
depend
tissu
type
allograft
thaw
allograft
must
use
discard
although
freez
effect
form
allograft
preserv
special
ship
storag
requir
motiv
develop
altern
method
avoid
ship
storag
limit
associ
frozen
tissu
anoth
preserv
option
freezedri
also
known
lyophil
use
ligament
bone
dermi
tissu
clean
process
freezedri
achiev
use
special
equip
reduc
residu
moistur
level
maintain
tissu
qualiti
may
vari
depend
tissu
type
lyophil
process
must
valid
monitor
storag
condit
must
maintain
appropri
moistur
level
advantag
freezedri
allograft
typic
store
year
ambient
temperatur
rehydr
need
ambient
temperatur
storag
need
special
freezer
special
ship
condit
howev
rehydr
time
lengthi
graft
may
never
fulli
rehydr
even
full
hydrat
may
abl
restor
tissu
nativ
properti
may
leav
tissu
fragil
state
make
suscept
damag
implant
exampl
studi
found
freezedri
bone
may
exhibit
brittl
weak
compar
frozen
glycerolpreserv
bone
could
especi
problemat
weightbear
graft
addit
preclin
clinic
report
rais
concern
immunolog
respons
freezedri
bone
tendon
spite
potenti
limit
freezedri
allograft
especi
ground
bone
void
filler
wide
use
clinic
success
mediaderiv
preserv
provid
conveni
ambient
storag
avoid
potenti
tissu
alter
inher
freezedri
tissu
processor
develop
solutionbas
method
ambient
preserv
current
two
main
preserv
use
allograft
name
solut
contain
ethanol
glycerol
although
salin
solut
use
bone
graft
ethanol
storag
tradit
econom
method
use
preserv
tissu
ecologist
natur
histori
museum
use
method
preserv
intact
specimen
mani
decad
also
use
forens
scienc
preserv
dna
sampl
ethanol
preserv
tissu
drive
water
tissu
cell
essenti
dehydr
tissu
common
ambient
temperatur
storag
method
treat
tissu
glycerol
act
humect
protect
tissu
keep
fulli
hydrat
glycerol
nontox
biodegrad
liquid
fda
classifi
gener
recogn
safe
common
ingredi
food
cosmet
pharmaceut
product
wide
use
dbm
allograft
spinal
applic
sinc
hold
moistur
glycerol
allow
allograft
store
ambient
temperatur
without
dri
ethanol
storag
commonli
use
adm
allograft
wherea
glycerol
storag
effect
use
bone
well
adm
clinic
studi
compar
glycerolpreserv
bone
either
freezedri
frozen
bone
author
found
glycerolpreserv
bone
perform
well
freezedri
frozen
bone
shorter
prepar
time
glycerol
alcohol
preserv
method
endow
tissu
desir
storag
characterist
elimin
need
lengthi
thaw
rehydr
time
accompani
frozen
freezedri
allograft
advantag
includ
eas
ship
storag
well
increas
flexibl
oper
room
staff
unlik
frozen
tissu
may
need
thaw
begin
well
advanc
schedul
surgeri
surgeon
decid
whether
use
glycerolor
alcoholpreserv
allograft
surgeri
alreadi
begun
allow
surgeon
option
make
realtim
decis
base
state
patient
given
proven
clinic
effect
conveni
ambientstor
allograft
like
tissu
bank
seek
develop
improv
storag
method
wider
varieti
tissu
human
allograft
tissu
play
increas
role
orthoped
practic
use
like
continu
increas
although
futur
develop
humanlik
synthet
xenograft
may
lead
declin
use
tradit
human
tissu
natur
matrix
structur
human
cellular
content
avail
allograft
hard
replic
limit
consider
note
previous
point
area
improv
subject
activ
research
within
industri
academia
includ
increas
cell
viabil
viabil
time
osteochondr
graft
increas
type
tissu
preserv
ambient
temperatur
storag
develop
timeeffici
less
aggress
disinfect
steril
technolog
rapid
test
method
detect
microb
virus
donor
tissu
even
recov
use
late
clinic
stage
antibiot
antivir
agent
assur
allograft
safeti
precondit
implant
cell
genet
transfect
transplant
cell
overexpress
key
factor
bmp
insulinlik
growth
factor
nontox
slowli
degrad
crosslink
method
allow
tissu
favor
initi
biomechan
properti
low
immunogen
also
eventu
remodel
modif
allograft
promot
recruit
key
cell
type
base
clinic
applic
seed
autolog
cell
situ
allogen
scaffold
isol
key
protein
allograft
chemotact
coat
combin
synthet
implant
modif
allow
inject
deploy
structur
nonstructur
graft
minim
invas
procedur
use
humanderiv
cell
perhap
genet
alter
direct
inject
clinic
site
provid
system
use
allograftsourc
induc
pluripot
stem
cell
sourc
person
medicin
treatment
eg
induc
cell
along
lineag
specif
treat
patient
uniqu
condit
expand
allograft
geometr
challeng
bone
void
fill
applic
use
allograft
move
forward
like
includ
basic
anatom
graft
also
dramat
modifi
human
compon
provid
inject
coat
cellular
therapi
combin
materi
allograft
wide
use
orthoped
practic
histor
tissu
typic
provid
simpl
intact
anatom
graft
tendon
long
bone
skin
forth
introduc
chapter
technolog
process
allograft
includ
physic
shape
deminer
decellular
preserv
methodolog
process
tend
alter
deconstruct
graft
chang
physic
state
design
yield
tissu
clinic
effect
advanc
disinfect
steril
technolog
assur
safeti
look
forward
human
tissu
serv
use
role
still
intact
structur
partial
deconstruct
alter
graft
howev
advanc
increasingli
propel
use
tissu
reconstruct
biolog
integr
construct
use
protein
isol
reconstitut
method
genet
alter
situ
cell
seed
advanc
